Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/214184
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sirico, Marianna | - |
dc.contributor.author | Virga, Alessandra | - |
dc.contributor.author | Conte, Benedetta | - |
dc.contributor.author | Urbini, Milena | - |
dc.contributor.author | Ulivi, Paola | - |
dc.contributor.author | Gianni, Caterina | - |
dc.contributor.author | Merloni, Filippo | - |
dc.contributor.author | Palleschi, Michela | - |
dc.contributor.author | Gasperoni, Marco | - |
dc.contributor.author | Curcio, Annalisa | - |
dc.contributor.author | Saha, Debjani | - |
dc.contributor.author | Buono, Giuseppe | - |
dc.contributor.author | Muñoz, Montserrat | - |
dc.contributor.author | De Giorgi, Ugo | - |
dc.contributor.author | Schettini, Francesco | - |
dc.date.accessioned | 2024-07-02T13:39:26Z | - |
dc.date.available | 2024-07-02T13:39:26Z | - |
dc.date.issued | 2023-01-01 | - |
dc.identifier.issn | 1040-8428 | - |
dc.identifier.uri | http://hdl.handle.net/2445/214184 | - |
dc.description.abstract | Neoadjuvant endocrine treatment (NET) associates to satisfactory rates of breast conservative surgery and conversions from inoperable to operable hormone receptor-positive (HR+)/HER2-negative breast cancer (BC), with less toxicities than neoadjuvant chemotherapy (NACT) and similar outcomes. Hence, it has been proposed as a logical alternative to NACT in patients with HR+/HER2- BC candidate to a neoadjuvant approach. Nevertheless, potential barriers to the widespread use of NET include the heterogeneous nature of patient response coupled with the long duration needed to achieve a clinical response. However, interest in NET has significantly increased in the last decade, owing to more in-depth investigation of several biomarkers for a more adequate patient selection and on-treatment benefit monitoring, such as PEPI score, Ki67 and genomic assays. This review is intended to describe the state-of-the-art regarding NET, its future perspectives and potential integration with molecular biomarkers for the optimal selection of patients, regimen and duration of (neo)adjuvant treatments. | - |
dc.format.extent | 13 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.critrevonc.2022.103900 | - |
dc.relation.ispartof | Critical Reviews in Oncology Hematology, 2023, vol. 181 | - |
dc.relation.uri | https://doi.org/10.1016/j.critrevonc.2022.103900 | - |
dc.rights | cc-by (c) Sirico, Marianna et al., 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0 | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Càncer de mama | - |
dc.subject.classification | Marcadors bioquímics | - |
dc.subject.classification | Endocrinologia | - |
dc.subject.classification | Tractament adjuvant del càncer | - |
dc.subject.other | Breast cancer | - |
dc.subject.other | Biochemical markers | - |
dc.subject.other | Endocrinology | - |
dc.subject.other | Adjuvant treatment of cancer | - |
dc.title | Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 729597 | - |
dc.date.updated | 2024-07-02T13:39:31Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 36565894 | - |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
256609.pdf | 644.52 kB | Adobe PDF | View/Open | |
Corrigendum Neoadjuvant endocrine therapy.pdf | 257.85 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License